What is MGC Pharmaceuticals?
MGC Pharmaceuticals Limited, established in 2005, is a biopharma company dedicated to developing standardized, affordable plant-derived medicines. Operating at the forefront of the phytocannabinoid market, the company aims to deliver high-regulatory compliance treatments for targeted global markets, positioning itself as an innovator in the emerging field of botanical therapeutics.
How much funding has MGC Pharmaceuticals raised?
MGC Pharmaceuticals has raised a total of $12.2M across 2 funding rounds:
Debt
$10M
Other Financing Round
$2.2M
Debt (2022): $10M with participation from Mercer Street Global Opportunity Fund
Other Financing Round (2023): $2.2M, investors not publicly disclosed
Key Investors in MGC Pharmaceuticals
Mercer Street Global Opportunity Fund
Mercer Street Global Opportunity Fund is an investment entity that has provided debt financing to MGC Pharmaceuticals, indicating a focus on capital solutions for growth-stage companies.
What's next for MGC Pharmaceuticals?
The substantial enterprise-level financing and recent strategic investment signal a pivotal growth phase for MGC Pharmaceuticals. This capital infusion is expected to accelerate the company's research and development initiatives, expand its market reach, and potentially facilitate further clinical trials and regulatory approvals for its plant-derived medicines. The company's focus on phytocannabinoids suggests a strategic move into a rapidly evolving and high-potential therapeutic area.
See full MGC Pharmaceuticals company page
